New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
If approved, DTX401 would be the first treatment to address the disease at its root cause
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Subscribe To Our Newsletter & Stay Updated
